8 results match your criteria: "The University of Texas MD Anderson Cancer Center; LECourt@mdanderson.org.[Affiliation]"
Eur J Cancer
May 2019
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0431, Houston, TX 77030, USA. Electronic address:
Background: It is estimated only 8-11% of patients with glioblastoma (GBM) enrol in clinical trials, limiting treatment development. We analysed the clinical and demographic features of patients with GBM enroled in clinical trials at the University of Texas MD Anderson Cancer Center (MDACC).
Methods: We reviewed the records of adult patients treated for primary GBM between 2007 and 2012 at the MDACC.
Cancer Genet
February 2019
Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States. Electronic address:
Astroblastoma is a rare glial neoplasm composed of cells that have broad processes oriented perpendicular to central vessels and often demonstrate vascular sclerosis. The WHO 2016 classification does not specify a grading system for astroblastoma, and categorizes them as well-differentiated or malignant. These broad classification rubrics, however, do not accurately predict clinical outcome.
View Article and Find Full Text PDFJ Natl Compr Canc Netw
May 2014
From the aDepartment of Neurology, The University of Mississippi Medical Center, Jackson, Mississippi; and bDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are uncommon malignant tumors occurring in adults, but have garnered attention because of a high rate of response to chemotherapy in early studies. However, no clinical trial had demonstrated benefit with the addition of chemotherapy to radiotherapy alone until the long-term results of RTOG 9402 and EORTC 26951. These studies revealed prolonged survival in patients with anaplastic gliomas harboring the 1p/19q codeletion when treated with PCV (procarbazine, lomustine, and vincristine) and radiation therapy compared with radiation alone.
View Article and Find Full Text PDFNeuro Oncol
September 2014
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (S.Y.-K., J.F.d.G., M.D.A., C.A.C., M.R.G., T.S.A.); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas (D.L., J.W., Y.Y.); Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.M.).
Background: Improvements in brain tumor treatments have led to an increase in the number of young women with brain tumors who are now considering pregnancy. The aim of this study is to evaluate the influence of pregnancy on brain tumor biology.
Methods: In this institutional review board-approved retrospective study, we searched the institution's database for patients with glial brain tumors who were pregnant at the time of diagnosis or became pregnant during the course of their illness.
Neuro Oncol
June 2014
Department of Neuro-Oncology (M.A., M.H., V.P.); Department of Biostatistics (K.H.), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Background: Patients with recurrent glioblastoma benefiting from bevacizumab are often treated indefinitely due to concerns regarding rebound tumor recurrence upon discontinuation. However, treatment is discontinued for reasons other than disease progression in a subset of these patients, the characteristics and outcomes of which are poorly defined.
Methods: Of 342 adults with recurrent glioblastoma in our database treated with bevacizumab, 82 received treatment for ≥ 6 months; of these, bevacizumab was discontinued for reasons other than tumor progression in 18 patients (Bev-D) and for disease progression in the remainder (Bev-S).
Neuro Oncol
March 2014
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (S.Y.-K., D.L., J.F.de-G.); Department of Neurology, The University of Mississippi Medical Center, Jackson, Mississippi (M.D.A.); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas (J.W., Y.Y.); Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.O., G.N.F.); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (P.D.B.).
Background: Gangliogliomas (GGs) represent <1% of primary brain tumors in adults. Little is known regarding prognostic features, clinical characteristics, or the impact of treatment on patient outcomes.
Methods: Our neuro-oncology longitudinal database was screened for patients with GG from 1992 to 2012.
Oncology (Williston Park)
April 2013
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract: Anaplastic oligodendroglioma (AO) is a rare malignant tumor occurring in adults. Despite early indications of chemosensitivity, no clinical trial had demonstrated a benefit of chemotherapy beyond that of radiotherapy alone. Now, however, the Radiation Therapy Oncology Group (RTOG) 9402 and the European Organisation for Research and Treatment of Cancer (EORTC) 26951 studies investigating PCV (procarbazine [Matulane], lomustine [CeeNU], and vincristine) and radiation therapy vs radiation alone both show improved outcomes in patients with the 1 p/19q codeletion who received PCV and radiation therapy.
View Article and Find Full Text PDFJ Neurosurg Spine
May 2013
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
Herpes simplex or herpes zoster reactivation after spinal surgery is rarely reported. This case report and review of the literature describes patients in whom this reactivation occurs to clarify the diagnosis and management. In addition to reporting their case, the authors reviewed case reports and series published between 1980 and 2012 found through a PubMed search.
View Article and Find Full Text PDF